טוען...
Severe Delayed-Onset Neutropenia Induced by Ocrelizumab
BACKGROUND: Ocrelizumab is an anti-CD20 monoclonal antibody that has been shown to reduce disability progression in primary progressive multiple sclerosis (MS). The adverse event profile is still being determined through postmarketing surveillance and case reports. OBJECTIVE: To report a case of sev...
שמור ב:
| הוצא לאור ב: | Neurohospitalist |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
SAGE Publications
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8022193/ https://ncbi.nlm.nih.gov/pubmed/33868559 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1941874420936438 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|